Roche Holding AG
RHHVF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.88 | -2.30 | -3.53 | -11.45 |
| FCF Yield | 7.40% | 5.95% | 6.02% | 5.22% |
| EV / EBITDA | 14.04 | 11.75 | 10.46 | 13.99 |
| Quality | ||||
| ROIC | 13.22% | 19.21% | 22.22% | 22.47% |
| Gross Margin | 73.90% | 72.94% | 67.77% | 68.72% |
| Cash Conversion Ratio | 2.19 | 1.30 | 1.36 | 1.40 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.47% | -1.27% | 2.76% | 0.72% |
| Free Cash Flow Growth | 31.79% | -17.43% | -15.61% | 38.32% |
| Safety | ||||
| Net Debt / EBITDA | 1.77 | 1.37 | 0.90 | 1.06 |
| Interest Coverage | 9.56 | 15.44 | 25.33 | 43.33 |
| Efficiency | ||||
| Inventory Turnover | 2.14 | 2.11 | 2.37 | 2.55 |
| Cash Conversion Cycle | 160.25 | 172.63 | 155.30 | 137.90 |